Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date
Positive mean estimated glomerular filtration rate (eGFR) slope observed in the 23 patients who had reached at least one-year follow-up, indicating notable improvements in renal function
All 18 patients who began study on enzyme replacement therapy (ERT) have been withdrawn from, and remain off, ERT
Data to support Accelerated Approval pathway expected in first half of 2025, with potential Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) anticipated in second half of 2025
Sangamo continues to advance business development discussions for a potential ST-920 collaboration
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.